Interruption of cancer screening services due to COVID-19 pandemic: lessons from previous disasters.

COVID-19 Cancer screening program Early detection of cancer Health services

Journal

Preventive medicine reports
ISSN: 2211-3355
Titre abrégé: Prev Med Rep
Pays: United States
ID NLM: 101643766

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 26 12 2020
revised: 05 04 2021
accepted: 08 05 2021
pubmed: 25 5 2021
medline: 25 5 2021
entrez: 24 5 2021
Statut: ppublish

Résumé

To review the scientific literature seeking lessons for the COVID-19 era that could be learned from previous health services interruptions that affected the delivery of cancer screening services. A systematic search was conducted up to April 17, 2020, with no restrictions on language or dates and resulted in 385 articles. Two researchers independently assessed the list and discussed any disagreements. Once a consensus was achieved for each paper, those selected were included in the review. Eleven articles were included. Three studies were based in Japan, two in the United States, one in South Korea, one in Denmark, and the remaining four offered a global perspective on interruptions in health services due to natural or human-caused disasters. No articles covered an interruption due to a pandemic. The main themes identified in the reviewed studies were coordination, communication, resource availability and patient follow-up. Lessons learned applied to the context of COVID-19 are that coordination involving partners across the health sector is essential to optimize resources and resume services, making them more resilient while preparing for future interruptions. Communication with the general population about how COVID-19 has affected cancer screening, measures taken to mitigate it and safely re-establish screening services is recommended. Use of mobile health systems to reach patients who are not accessing services and the application of resource-stratified guidelines are important considerations. More research is needed to explore best strategies for suspending, resuming and sustaining cancer screening programs, and preparedness for future disruptions, adapted to diverse health care systems.

Identifiants

pubmed: 34026465
doi: 10.1016/j.pmedr.2021.101399
pii: S2211-3355(21)00089-9
pmc: PMC8126519
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

101399

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Health Serv Res. 2021 Feb;56(1):95-101
pubmed: 33146429
Science. 2020 Jun 19;368(6497):1290
pubmed: 32554570
J Clin Oncol. 2020 Jul 1;38(19):2201-2205
pubmed: 32343643
Ann Oncol. 2008 Apr;19(4):614-22
pubmed: 18024988
JCO Glob Oncol. 2021 Feb;7:311-323
pubmed: 33617304
Pediatrics. 2007 Oct;120(4):e749-55
pubmed: 17908732
BMC Cancer. 2017 Jun 19;17(1):423
pubmed: 28629330
Disaster Med Public Health Prep. 2014 Dec;8(6):471-6
pubmed: 25427564
Gastroenterology. 2020 Sep;159(3):1164-1166.e3
pubmed: 32425228
Disaster Med Public Health Prep. 2020 Apr 03;:1-6
pubmed: 32241311
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Glob Oncol. 2019 Oct;5:1-12
pubmed: 31600086
JAMA Oncol. 2020 Sep 1;6(9):1429-1433
pubmed: 32761149
Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2695-2700
pubmed: 30360593
J Hematol Oncol. 2020 Nov 4;13(1):147
pubmed: 33148289
J Oncol Pract. 2019 Jul;15(7):e607-e615
pubmed: 31150312
PLoS One. 2020 Mar 11;15(3):e0229924
pubmed: 32160221
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
JAMA. 2019 Jul 16;322(3):269-271
pubmed: 31310288
Pharmaceuticals (Basel). 2020 Jul 06;13(7):
pubmed: 32640723
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Eur J Cancer. 2012 Sep;48(14):2212-8
pubmed: 22424881
J Healthc Leadersh. 2016 Oct 27;8:61-69
pubmed: 29355205
Saf Sci. 2020 Aug;128:104773
pubmed: 32296266
Prehosp Disaster Med. 1997 Apr-Jun;12(2):120-31
pubmed: 10186995
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Am Soc Clin Oncol Educ Book. 2018 May 23;38:433-440
pubmed: 30231320
JCO Glob Oncol. 2020 Feb;6:180-181
pubmed: 32031454
J Glob Health. 2019 Jun;9(1):010406
pubmed: 30701070
Lancet Oncol. 2020 Jun;21(6):750-751
pubmed: 32359403

Auteurs

Douglas M Puricelli Perin (DM)

Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Tess Christensen (T)

Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands.

Andrea Burón (A)

IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain.

Jennifer S Haas (JS)

Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Aruna Kamineni (A)

Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.

Nora Pashayan (N)

Department of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.

Linda Rabeneck (L)

Prevention and Cancer Control, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Robert Smith (R)

Prevention and Early Detection Department, American Cancer Society, Atlanta, Georgia.

Miriam Elfström (M)

Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Regional Cancer Center of Stockholm Gotland, Stockholm, Sweden.

Mireille J M Broeders (MJM)

Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands.
Dutch Expert Centre for Screening, Nijmegen, the Netherlands.

Classifications MeSH